Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Procella Therapeutics
Tullinge, Stockholm County, Swedenprocella.se ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Other
01
Overview
Procella Therapeutics is developing a proprietary cardiac stem/progenitor cell technology ("PROC‑001") that has demonstrated engraftment and regenerative potential in animal models of heart damage. The company is optimizing manufacturing and collaborating with AstraZeneca to advance toward clinical trials. No human clinical results have been reported yet; all published data are pre-clinical.
- Therapeutic areas
- Cardiovascular
- Modalities
- Cell therapyStem cell therapyCardiac progenitor cell therapy
- Industry
- Biotech
02
Partnerships
AstraZeneca (major R&D collaboration for cardiovascular regenerative therapies)Smartwise/SmartCella group companies for delivery technologies
Beyond the preview
Go deeper on Procella Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Procella Therapeutics.